Literature DB >> 6721884

Costs and outcomes in rheumatoid arthritis and osteoarthritis.

M H Liang, M Larson, M Thompson, H Eaton, E McNamara, R Katz, J Taylor.   

Abstract

A prospective descriptive study was done on the direct and indirect costs to ambulatory patients with rheumatoid arthritis and osteoarthritis, stratified at study entry by level of function. Measures of health status over a 1-year period were taken. On a yearly basis, in 1979 dollars, patients spent an average of $147 for arthritis medications, aids, and devices, and $207 for outpatient visits. A small number were hospitalized and incurred an average charge of $245, and an additional $84 for physician fees. In addition to direct monetary costs, patients averaged 6.8 days of restricted activity costs, patients averaged 6.8 days of restricted activity per month, in some cases so severe as to confine patients to bed for an average of 1.3 days per month. Among students and working patients, 2.5 work-days per month were lost due to arthritis, and 30% reported that they were unemployed or retired because of impaired health. Functional capacity and specific diagnosis on entry to the study were the most important determinants of arthritis-related expenditures. Both direct and indirect costs varied considerably from the observed average. Twenty percent of patients incurred no costs for arthritis-related purchases, 42+ had no costs for outpatient visits, and 93% had no inpatient costs. Yet for some patients, the financial burden was very high.

Entities:  

Mesh:

Year:  1984        PMID: 6721884     DOI: 10.1002/art.1780270507

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  19 in total

1.  Reprocessing data to form QALYs.

Authors:  J Coast
Journal:  BMJ       Date:  1992-07-11

Review 2.  International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review.

Authors:  Hubertus Rosery; Rito Bergemann; Stefanie Maxion-Bergemann
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 3.  Acetaminophen for osteoarthritis.

Authors:  T E Towheed; L Maxwell; M G Judd; M Catton; M C Hochberg; G Wells
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

Review 4.  Pharmacoeconomics of nonsteroidal anti-inflammatory drugs (NSAIDs).

Authors:  H A Wynne; M Campbell
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

5.  Cost analysis of prophylaxis with antibiotics to prevent infected knee arthroplasty.

Authors:  S Bengtson; L Borgquist; L Lidgren
Journal:  BMJ       Date:  1989-09-16

Review 6.  The costs of rheumatoid arthritis.

Authors:  S H Allaire; M J Prashker; R F Meenan
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

Review 7.  A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings.

Authors:  D P Lubeck
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

8.  Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity.

Authors:  S M M Verstappen; A Boonen; H Verkleij; J W J Bijlsma; E Buskens; J W G Jacobs
Journal:  Ann Rheum Dis       Date:  2005-04-28       Impact factor: 19.103

9.  Determinants of direct costs in Dutch rheumatoid arthritis patients.

Authors:  S M M Verstappen; H Verkleij; J W J Bijlsma; E Buskens; A A Kruize; A H M Heurkens; M J Van Der Veen; J W G Jacobs
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

10.  The relationship between coping and psychological well-being among people with osteoarthritis: a problem-specific approach.

Authors:  S J Blalock; B M Devellis; K B Giorgino
Journal:  Ann Behav Med       Date:  1995
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.